Teva and Eagle try to block Bendeka generic

Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka (bendamustine), arguing its patents still have plenty of time to run.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

11th circ ‘eviscerated’ orphan drug rights, says petition

14 April 2022 New Jersey pharma company Jacobus Pharmaceutical has asked the US Supreme Court to review an 11th Circuit verdict that it claims “eviscerated” decades of precedent regarding Orphan Drug Act exclusivity.

Generics

Fed Circ upholds Teva cancer drug patents

17 August 2021 The US Court of Appeals for the Federal Circuit has affirmed a Delaware court ruling upholding the validity of cancer drug patents owned by Teva Pharmaceuticals.

Americas

FDA warns of ‘grave’ knock-on effects from Eagle decision

29 May 2020 The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Teva and Eagle try to block Bendeka generic

More on this story

Editor's picks

Editor's picks

More features